Can Stereotactic Body Radiotherapy Really Be Considered the Preferred Treatment in Large Hepatocellular Carcinoma? [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 2, 2016 Category: Cancer & Oncology Authors: De Bari, Ozsahin, Bize, Boussaha, Deplanque, Wagner, Bourhis, Denys Tags: CORRESPONDENCE Source Type: research
Is Stereotactic Body Radiotherapy Better Than Radiofrequency Ablation for the Treatment of Hepatocellular Carcinoma? [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 2, 2016 Category: Cancer & Oncology Authors: Yang, Lo, Huang Tags: CORRESPONDENCE Source Type: research
Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline [ASCO SPECIAL ARTICLE]
Purpose
To provide evidence-based recommendations to oncologists and others for the treatment of patients with metastatic pancreatic cancer.
Methods
American Society of Clinical Oncology convened an Expert Panel of medical oncology, radiation oncology, surgical oncology, gastroenterology, palliative care, and advocacy experts to conduct a systematic review of the literature from April 2004 to June 2015. Outcomes were overall survival, disease-free survival, progression-free survival, and adverse events.
Results
Twenty-four randomized controlled trials met the systematic review criteria.
Recommendations
A multiphase comp...
Source: Journal of Clinical Oncology - August 2, 2016 Category: Cancer & Oncology Authors: Sohal, Mangu, Khorana, Shah, Philip, OReilly, Uronis, Ramanathan, Crane, Engebretson, Ruggiero, Copur, Lau, Urba, Laheru Tags: ASCO Guidelines, Diagnosis & Staging, Chemotherapy, Palliative Care ASCO SPECIAL ARTICLE Source Type: research
Lack of Effectiveness of Neutropenic Diet and Social Restrictions as Anti-Infective Measures in Children With Acute Myeloid Leukemia: An Analysis of the AML-BFM 2004 Trial [Palliative and Supportive Care]
Conclusion
The lack of effectiveness of dietary restrictions and restrictions regarding social contacts and pets should result in reconsideration of anti-infective policies. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 2, 2016 Category: Cancer & Oncology Authors: Tramsen, Salzmann-Manrique, Bochennek, Klingebiel, Reinhardt, Creutzig, Sung, Lehrnbecher Tags: Supportive Care Palliative and Supportive Care Source Type: research
Quality of Life in Patients With Advanced Cancer: Differential Association With Performance Status and Systemic Inflammatory Response [Palliative and Supportive Care]
Conclusion
Systemic inflammation was associated with quality-of-life parameters independent of PS in patients with advanced cancer. Further investigation of these relationships in longitudinal studies and investigations of possible effects of attenuating systemic inflammation are now warranted. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 2, 2016 Category: Cancer & Oncology Authors: Laird, Fallon, Hjermstad, Tuck, Kaasa, Klepstad, McMillan Tags: Bioinformatics, Population and observational studies (SEER, WHI observational, etc.), Quality of Life, Supportive Care Palliative and Supportive Care Source Type: research
Phase II Study of Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) As Part of Lung-Sparing Multimodality Therapy in Patients With Malignant Pleural Mesothelioma [Thoracic Oncology]
Conclusions
Hemithoracic IMPRINT for malignant pleural mesothelioma (MPM) is safe and has an acceptable rate of RP. Its incorporation with chemotherapy and P/D forms a new lung-sparing treatment paradigm for patients with locally advanced MPM. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 2, 2016 Category: Cancer & Oncology Authors: Rimner, Zauderer, Gomez, Adusumilli, Parhar, Wu, Woo, Shen, Ginsberg, Yorke, Rice, Tsao, Rosenzweig, Rusch, Krug Tags: Radiation Oncology, Surgery, Radiation, Chemotherapy, Combined Modality Thoracic Oncology Source Type: research
Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers [Breast Cancer]
Conclusion
These CHEK2*1100delC breast cancer risk estimates provide a basis for incorporating CHEK2*1100delC into breast cancer risk prediction models and into guidelines for intensified screening and follow-up. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 2, 2016 Category: Cancer & Oncology Authors: Schmidt, Hogervorst, van Hien, Cornelissen, Broeks, Adank, Meijers, Waisfisz, Hollestelle, Schutte, van den Ouweland, Hooning, Andrulis, Anton-Culver, Antonenkova, Antoniou, Arndt, Bermisheva, Bogdanova, Bolla, Brauch, Brenner, Bruning, Burwinkel, Chang-C Tags: Epidemiology, Statistical Genetics, Risk factors, Genetic epidemiology Breast Cancer Source Type: research
Exercise and Risk of Cardiovascular Events in Women With Nonmetastatic Breast Cancer [Breast Cancer]
Conclusion
Exercise is associated with substantial, graded reductions in the incidence of cardiovascular events in women with nonmetastatic breast cancer. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 2, 2016 Category: Cancer & Oncology Authors: Jones, Habel, Weltzien, Castillo, Gupta, Kroenke, Kwan, Quesenberry, Scott, Sternfeld, Yu, Kushi, Caan Tags: Epidemiology, Behavioral and Lifestyle Risk Factors Breast Cancer Source Type: research
CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers [Gastrointestinal Cancer]
Conclusion
In combination with cetuximab, ECF and FOLFOX had similar efficacy, but FOLFOX was better tolerated. Although differences were nonsignificant, IC plus cetuximab seemed to be the least effective and most toxic of the three regimens tested. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 2, 2016 Category: Cancer & Oncology Authors: Enzinger, Burtness, Niedzwiecki, Ye, Douglas, Ilson, Villaflor, Cohen, Mayer, Venook, Benson, Goldberg Tags: Chemotherapy Gastrointestinal Cancer Source Type: research
Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial [Gastrointestinal Cancer]
Conclusion
In this phase II trial, regorafenib was effective in prolonging PFS in refractory advanced gastric adenocarcinoma. Regional differences were found, but regorafenib was effective in both regional groups. A phase III trial is planned. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 2, 2016 Category: Cancer & Oncology Authors: Pavlakis, Sjoquist, Martin, Tsobanis, Yip, Kang, Bang, Alcindor, OCallaghan, Burnell, Tebbutt, Rha, Lee, Cho, Lipton, Wong, Strickland, Kim, Zalcberg, Simes, Goldstein Tags: Chemotherapy Gastrointestinal Cancer Source Type: research
Effect of Pathologic Tumor Response and Nodal Status on Survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy Trial [Gastrointestinal Cancer]
Conclusion
Lymph node metastases and not pathologic response to chemotherapy was the only independent predictor of survival after chemotherapy plus resection in the MAGIC trial. Prospective evaluation of whether omitting postoperative chemotherapy and/or switching to a noncross-resistant regimen in patients with lymph node-positive disease whose tumor did not respond to preoperative epirubicin, cisplatin, and fluorouracil may be appropriate. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 2, 2016 Category: Cancer & Oncology Authors: Smyth, Fassan, Cunningham, Allum, Okines, Lampis, Hahne, Rugge, Peckitt, Nankivell, Langley, Ghidini, Braconi, Wotherspoon, Grabsch, Valeri Tags: Clinical Trials, Prognostic Studies, Diagnosis & Staging, Surgery, Chemotherapy, Combined Modality Gastrointestinal Cancer Source Type: research
Comprehensive Audiometric Analysis of Hearing Impairment and Tinnitus After Cisplatin-Based Chemotherapy in Survivors of Adult-Onset Cancer [Treatment-Related Complications]
Conclusion
Follow-up of adult-onset cancer survivors given cisplatin should include routine inquiry for hearing status and tinnitus, referral to audiologists as clinically indicated, and hypertension control. Patients should be urged to avoid noise exposure, ototoxic drugs, and other factors that further damage hearing. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 2, 2016 Category: Cancer & Oncology Authors: Frisina, Wheeler, Fossa, Kerns, Fung, Sesso, Monahan, Feldman, Hamilton, Vaughn, Beard, Budnick, Johnson, Ardeshir-Rouhani-Fard, Einhorn, Lipshultz, Dolan, Travis Tags: Chemotherapy, Outcomes Research Treatment-Related Complications Source Type: research
Baseline Prostate-Specific Antigen Levels in Midlife Predict Lethal Prostate Cancer [Urologic Oncology]
Conclusion
PSA levels in midlife strongly predict future lethal PCa in a US cohort subject to opportunistic screening. Risk-stratified screening on the basis of midlife PSA should be considered in men age 45 to 59 years. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 2, 2016 Category: Cancer & Oncology Authors: Preston, Batista, Wilson, Carlsson, Gerke, Sjoberg, Dahl, Sesso, Feldman, Gann, Kibel, Vickers, Mucci Tags: Epidemiology & Prevention Urologic Oncology Source Type: research
Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study [Hematologic Malignancy]
Conclusion
Nivolumab was well tolerated and exhibited antitumor activity in extensively pretreated patients with relapsed or refractory B- and T-cell lymphomas. Additional studies of nivolumab in these diseases are ongoing. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 2, 2016 Category: Cancer & Oncology Authors: Lesokhin, Ansell, Armand, Scott, Halwani, Gutierrez, Millenson, Cohen, Schuster, Lebovic, Dhodapkar, Avigan, Chapuy, Ligon, Freeman, Rodig, Cattry, Zhu, Grosso, Bradley Garelik, Shipp, Borrello, Timmerman Tags: Non-Hodgkin's Lymphoma Hematologic Malignancy Source Type: research
PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome [Rapid Communication]
Conclusion
PD-L1/PD-L2 alterations are a defining feature of cHL. Amplification of 9p24.1 is more common in patients with AS disease and associated with shorter PFS in this series. Further analyses of 9p24.1 alterations in patients treated with standard cHL induction regimens or checkpoint blockade are warranted. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 2, 2016 Category: Cancer & Oncology Authors: Roemer, Advani, Ligon, Natkunam, Redd, Homer, Connelly, Sun, Daadi, Freeman, Armand, Chapuy, de Jong, Hoppe, Neuberg, Rodig, Shipp Tags: Biology & Immunology, Rapid Communications, Rapid Communications Source Type: research
